A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Kiesewetter, B, Willenbacher, E, Willenbacher, W, Egle, A, Neumeister, P, Voskova, D, Mayerhoefer, ME, Simonitsch-Klupp, I, Melchardt, T, Greil, R, Raderer, M.

http://www.ncbi.nlm.nih.gov/pubmed/27879257